Inovio investors warned of April 7, 2026 deadline to join securities class action over misleading FDA approval claims.

Faruqi & Faruqi, LLP reminds Inovio Pharmaceuticals investors of the April 7, 2026 deadline to seek lead plaintiff status in a securities class action lawsuit. The suit alleges Inovio and its executives made false or misleading statements about manufacturing issues with their CELLECTRA device and overstated the regulatory prospects of their INO-3107 drug. The FDA rejected Inovio's accelerated approval application for INO-3107, leading to a 24.45% stock price drop. Investors who suffered losses between October 10, 2023, and December 26, 2025, are encouraged to contact the law firm to discuss their legal options.